Intima Bioscience News Today

PRESS RELEASE Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio ... | May 5, 2023

Investegate announcements from MaxCyte, Inc., Preliminary Unaudited Q4 &FY 2022 Revenue Results

Transgene’s Combined General Meeting of May 25, 2022 Strasbourg, France, May 25, 2022, 05:45 p.m. CEST – The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonth...

Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene's (Paris:TNG) shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company's headquarters (400 boulevard

MXCT earnings call for the period ending March 31, 2022.

The roles of Chairman and Chief Executive Officer will be separated. Dr. Riva proposed as new independent Director and non-executive Chairman of the Board. With more than 30 years of experience

GAITHERSBURG, Md., March 22, 2022 /PRNewswire/ -- MaxCyte, Inc., (NASDAQ: MXCT) (LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies

Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1. 

MaxCyte inks platform pact with Intima Bioscience

Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.